15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 4 firms covering Neuropace Inc, 4 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets are tightly clustered, $20.00 to $20.00, so the covering firms are broadly aligned. The average target of $20.00 sits 31% above the current $15.27. The rating mix has stayed broadly stable, with Buy-side ratings easing from 5 to 4 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.10 next quarter toward $-0.29 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS4 ratings
Moderate Buy
Strong Buy00%
Buy4100%
Hold00%
Sell00%
Strong Sell00%
Based on 4 analysts giving stock ratings to Neuropace Inc.
As of Jul, 4 of 4 firms rate NPCE a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
NPCE EPS & revenue forecast
EPS · NEXT QUARTER
$-0.10
Range $-0.16 – $-0.03 · 8 analysts · -8% YoY
Next period, 8 analysts expect Neuropace Inc to earn $-0.10 a share (range $-0.16 – $-0.03), versus $-0.11 a year earlier. Full-year consensus is $-0.54, growing to $-0.29 the year after.
REVENUE · NEXT QUARTER
$27.1M
Range $26.3M – $27.7M · 8 analysts · -1% YoY
Revenue is expected to reach $27.1M (range $26.3M – $27.7M), -1.0% year-over-year. Full-year consensus is $99.9M, rising to $123.4M next year.
Top analysts covering Neuropace Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on NPCE.
#1
Ross Osborn
Cantor Fitzgerald · Rank #139
Buy
$16.00+4.8% to target
Overall win rate
34%
+ Follow
#2
Yi Chen
HC Wainwright & Co. · Rank #238
Buy
$20.00+31.0% to target
Overall win rate
34%
+ Follow
#3
RP
Rohin Patel
JP Morgan
Buy
$20.00+31.0% to target
Coverage
—
+ Follow
#4
PS
Priya Sachdeva
UBS
Buy
$22.00+44.1% to target
Coverage
—
+ Follow
#5
MP
Michael Polark
Wolfe Research
Buy
$13.00-14.9% to target
Coverage
—
+ Follow
NPCE stock forecast FAQ
What is NPCE's average 12-month price target?+
The 1 analysts with a live target average $20.00 for Neuropace Inc over the next 12 months, ranging from a $20.00 high to a $20.00 low.
Is NPCE stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 4 analyst ratings, 4 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
How many Wall Street analysts cover NPCE?+
4 analysts have an active rating on Neuropace Inc, and 1 firms carry a live 12-month price target.
Who is the most accurate analyst covering NPCE?+
Among analysts who currently cover NPCE, Ross Osborn of Cantor Fitzgerald has the strongest overall Quantellect track record (Rank #139). Their current call is Buy with a $16.00 target.
What is Neuropace Inc's projected EPS for next quarter?+
The consensus estimate is $-0.10 per share (range $-0.16 – $-0.03) across 8 analysts. Full-year EPS is projected at $-0.54, rising to $-0.29 the following year.
How much revenue is Neuropace Inc expected to report next quarter?+
Consensus revenue is $27.1M (range $26.3M – $27.7M). Full-year revenue is projected at $99.9M, growing to $123.4M next year.
Have analysts been upgrading or downgrading NPCE lately?+
As of Jul, 4 of 4 firms rate NPCE a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their NPCE calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
